GB1450960A - Stabilization of prostaglandins - Google Patents

Stabilization of prostaglandins

Info

Publication number
GB1450960A
GB1450960A GB5004773A GB5004773A GB1450960A GB 1450960 A GB1450960 A GB 1450960A GB 5004773 A GB5004773 A GB 5004773A GB 5004773 A GB5004773 A GB 5004773A GB 1450960 A GB1450960 A GB 1450960A
Authority
GB
United Kingdom
Prior art keywords
prostaglandins
oct
pge
cyclodextrin clathrates
cyclopentane ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5004773A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of GB1450960A publication Critical patent/GB1450960A/en
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1450960 Compositions containing cyclodextrin clathrates of prostaglandins ONO PHARMACEUTICAL CO Ltd 26 Oct 1973 [27 Oct 1972] 50047/73 Heading A5B [Also in Divisions C2 and C3] Pharmaceutical compositions, suitable for oral or parenteral administration, contain cyclodextrin clathrates of prostaglandins having a cyclopentane ring of the PGE type and Vitamin C or citric acid in an amount sufficient to inhibit conversion of the PGE cyclopentane ring into the cyclopentene ring of a prostaglandin A, and, pharmaceutically acceptable inert solid or liquid carriers or diluents. Reference has been directed by the comptroller to Specifications 1364125, 1362956, 1362955, 1348162, 1156465 and 1040544.
GB5004773A 1972-10-27 1973-10-26 Stabilization of prostaglandins Expired GB1450960A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10777672A JPS5443570B2 (en) 1972-10-27 1972-10-27

Publications (1)

Publication Number Publication Date
GB1450960A true GB1450960A (en) 1976-09-29

Family

ID=14467713

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5004773A Expired GB1450960A (en) 1972-10-27 1973-10-26 Stabilization of prostaglandins

Country Status (4)

Country Link
JP (1) JPS5443570B2 (en)
DE (1) DE2353797A1 (en)
FR (1) FR2204421B1 (en)
GB (1) GB1450960A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451457A (en) * 1981-02-18 1984-05-29 Kureha Kagaku Kogyo Kabushiki Kaisha Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB2173400A (en) * 1985-04-01 1986-10-15 Chinoin Gyogyszer Es Vegyeszet Dusting powders
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
AU623779B2 (en) * 1989-05-24 1992-05-21 Rhone-Poulenc Sante New porus pharmaceutical form and its preparation
EP0796076A1 (en) * 1994-12-06 1997-09-24 Isp Investments Inc. N-vinyl lactam polymer containing tablets of low friability and high rate of dissolution

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS536416A (en) * 1976-07-01 1978-01-20 Emu Esu Shii Yuugen 55fluorouracli inclusion compound
JPS53133623A (en) * 1977-04-21 1978-11-21 Fujimoto Seiyaku Kk Medical preparation including antiicholine active medicine by cyclodextrin analogue
HU176217B (en) * 1978-11-20 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-chamomille inclusion complex and compositions containing thereof
DE3162914D1 (en) * 1981-01-10 1984-05-10 Chinoin Gyogyszer Es Vegyeszet Stabilized prostaglandin tablets for topical use with regulated dissolving speed and process for preparing them
DE3304864A1 (en) * 1983-02-12 1984-08-16 Bayer Ag, 5090 Leverkusen Adsorbates of prostaglandins
JPH075464B2 (en) * 1985-07-08 1995-01-25 中外製薬株式会社 Stable nicorandil formulation
JPWO2006075690A1 (en) * 2005-01-14 2008-06-12 小野薬品工業株式会社 Stable pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3504019A (en) * 1967-02-20 1970-03-31 American Home Prod Prostaglandin purification process
JPS503362B1 (en) * 1970-06-10 1975-02-04
US3644638A (en) * 1970-08-24 1972-02-22 American Home Prod Compositions and methods for relieving bronchial spasm with prostanoic acids and esters

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451457A (en) * 1981-02-18 1984-05-29 Kureha Kagaku Kogyo Kabushiki Kaisha Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB2173400A (en) * 1985-04-01 1986-10-15 Chinoin Gyogyszer Es Vegyeszet Dusting powders
GB2173400B (en) * 1985-04-01 1989-06-28 Chinoin Gyogyszer Es Vegyeszet New dusting powders containing bioactive substance and process for their preparation.
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
AU623779B2 (en) * 1989-05-24 1992-05-21 Rhone-Poulenc Sante New porus pharmaceutical form and its preparation
EP0796076A1 (en) * 1994-12-06 1997-09-24 Isp Investments Inc. N-vinyl lactam polymer containing tablets of low friability and high rate of dissolution
EP0796076A4 (en) * 1994-12-06 2003-03-12 Isp Investments Inc N-vinyl lactam polymer containing tablets of low friability and high rate of dissolution

Also Published As

Publication number Publication date
FR2204421B1 (en) 1977-09-09
JPS5443570B2 (en) 1979-12-20
JPS4966816A (en) 1974-06-28
DE2353797A1 (en) 1974-05-09
FR2204421A1 (en) 1974-05-24

Similar Documents

Publication Publication Date Title
IE35326B1 (en) Clathrate prostaglandins and compositions containing same
GB1450960A (en) Stabilization of prostaglandins
ZA739543B (en) Free-flowing, directly tablettable, pharmaceutically active substances
SE7612262L (en) KETOPHOSPHONATE INTERMEDIATE PRODUCTS AND PROCEDURES
ES444047A1 (en) Prostanoic acid derivatives
GB1442925A (en) Triamcinolone derivative
GB1450691A (en) Prostaglandin analogues
GB1484591A (en) Prostaglandin compositions
AU502576B2 (en) 11-deoxy prostaglandins
GB1419221A (en) Calthrate prostaglandins and compositions containing same
GB1421589A (en) Salicylanilide derivatives
ES422831A1 (en) Cyclopentane derivatives
GB1449882A (en) Prostaglandin analogues
IL45215A0 (en) Novel prostaglandin derivatives,their production and pharmaceutical compositions containing them
GB1498857A (en) Antidepressant composition
JPS52138580A (en) Cyclodextrin derivatives
GB1440601A (en) Oxaprostaglandins
GB1230681A (en)
CA1033728A (en) Pharmaceutically useful prostanoic acid derivatives
ES377166A1 (en) Derivatives of 2-(4-aryl-1-piperazyl)-bicyclo{8 3.3.1{9 nonan-9-ones
AU476756B2 (en) PHARMACOLOGICALLY ACTIVE 4, 8-DIMETHOXY-FURO-(3',2'-F) BENZOXAZOL-2-yl ACETHYDROXAMIC ACID
GB1230468A (en)
GB1411065A (en) Prostaglandin compounds
GB1350237A (en) Cyclopentane derivatives and the preparation thereof
GB1293695A (en) p-AMINO-PHENOL DERIVATIVES

Legal Events

Date Code Title Description
CSNS Application of which complete specification have been accepted and published, but patent is not sealed